nivatrotamab (GD2xCD3) / Memorial Sloan-Kettering Cancer Center, Y-mAbs Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nivatrotamab (GD2xCD3) / Y-mAbs Therap
NCT03860207: Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Terminated
1/2
12
US
Humanized 3F8 Bispecific Antibody, Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb), Blood draw
Y-mAbs Therapeutics
Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
10/21
10/21
NCT04750239: Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Terminated
1/2
3
US
Nivatrotamab
Y-mAbs Therapeutics
SCLC
04/22
04/22

Download Options